Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.

Biocon awaits site inspection after pandemic-amplified delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes they can still make good and garner market share. All eyes are also on traction for their insulin glargine via increased share of formulary contracts.

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.